Affordable Access

Access to the full text

WHO malaria nucleic acid amplification test external quality assessment scheme: results of distribution programmes one to three

  • Cunningham, Jane A.1
  • Thomson, Rebecca M.2
  • Murphy, Sean C.3
  • de la Paz Ade, Maria4
  • Ding, Xavier C.5
  • Incardona, Sandra5
  • Legrand, Eric6
  • Lucchi, Naomi W.7
  • Menard, Didier6
  • Nsobya, Samuel L.8
  • Saez, Agatha C.9
  • Chiodini, Peter L.9, 10
  • Shrivastava, Jaya9, 10
  • 1 World Health Organization, Geneva, Switzerland , Geneva (Switzerland)
  • 2 Independent Consultant, London, UK , London (United Kingdom)
  • 3 Fred Hutchinson Cancer Research Center, Seattle, USA , Seattle (United States)
  • 4 Pan American Health Organization/World Health Organization, Washington, DC, USA , Washington (United States)
  • 5 Foundation for Innovative New Diagnostics, Geneva, Switzerland , Geneva (Switzerland)
  • 6 Institut Pasteur, INSERM U1201/CNRS ERL9195, Paris, France , Paris (France)
  • 7 Malaria Branch, Division of Parasitic Diseases and MalariaCenter for Global Health, Centers for Disease Control and Prevention, Atlanta, USA , Atlanta (United States)
  • 8 Makerere University, Kampala, Uganda , Kampala (Uganda)
  • 9 UK NEQAS Parasitology, Public Health England, London, UK , London (United Kingdom)
  • 10 The Hospital for Tropical Diseases, London, UK , London (United Kingdom)
Published Article
Malaria Journal
Springer (Biomed Central Ltd.)
Publication Date
Mar 30, 2020
DOI: 10.1186/s12936-020-03200-0
Springer Nature


BackgroundThe World Health Organization (WHO) recommends parasite-based diagnosis of malaria. In recent years, there has been surge in the use of various kinds of nucleic-acid amplification based tests (NAATs) for detection and identification of Plasmodium spp. to support clinical care in high-resource settings and clinical and epidemiological research worldwide. However, these tests are not without challenges, including lack (or limited use) of standards and lack of reproducibility, due in part to variation in protocols amongst laboratories. Therefore, there is a need for rigorous quality control, including a robust external quality assessment (EQA) scheme targeted towards malaria NAATs. To this effect, the WHO Global Malaria Programme worked with the UK National External Quality Assessment Scheme (UK NEQAS) Parasitology and with technical experts to launch a global NAAT EQA scheme in January 2017.MethodsPanels of NAAT EQA specimens containing five major species of human-infecting Plasmodium at various parasite concentrations and negative samples were created in lyophilized blood (LB) and dried blood spot (DBS) formats. Two distributions per year were sent, containing five LB and five DBS specimens. Samples were tested and validated by six expert referee laboratories prior to distribution. Between 37 and 45 laboratories participated in each distribution and submitted results using the online submission portal of UK NEQAS. Participants were scored based on their laboratory’s stated capacity to identify Plasmodium species, and individual laboratory reports were sent which included performance comparison with anonymized peers.ResultsAnalysis of the first three distributions revealed that the factors that most significantly affected performance were sample format (DBS vs LB), species and parasite density, while laboratory location and the reported methodology used (type of nucleic acid extraction, amplification, or DNA vs RNA target) did not significantly affect performance. Referee laboratories performed better than non-referee laboratories.ConclusionsGlobally, malaria NAAT assays now inform a range of clinical, epidemiological and research investigations. EQA schemes offer a way for laboratories to assess and improve their performance, which is critical to safeguarding the reliability of data and diagnoses especially in situations where various NAAT methodologies and protocols are in use.

Report this publication


Seen <100 times